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Abstract
Background & Aims—Patients with inflammatory bowel disease (IBD) may be at increased 
risk for infectious complications. We aimed to determine the risk of pneumonia in IBD and how 
biologic and immunosuppressive medications affect this risk.
Methods—We performed a retrospective cohort and a nested case-control study using 
administrative data from IMS Health Inc, LifeLink™ Health Plan Claims Database. In the cohort, 
IBD patients were matched to 4 individuals without IBD. Pneumonia risk was evaluated by 
incidence rate ratio (IRR) and by adjusted Cox proportional hazards models. In the nested case-
control analysis, 4856 IBD patients with pneumonia were matched to up to 4 IBD patients without 
pneumonia by incidence density sampling. Conditional logistic regression was used to determine 
associations between medications and pneumonia.
Results—The cohort included 50,932 patients with Crohn's disease (CD), 56,403 patients with 
ulcerative colitis (UC), and 1,269 with unspecified IBD; matched to 434,416 individuals without 
IBD. The IBD cohort had an increased pneumonia risk when compared to non-IBD (IRR 1.82, 
95% CI 1.75-1.88). In adjusted Cox analysis, pneumonia risk remained increased for the IBD vs. 
non-IBD cohort (HR 1.54, 95% CI 1.49-1.60), with increased risk in both CD (HR 1.71, 95% CI 
1.62-1.80) and UC (HR 1.41, 95% CI 1.34-1.48). In the nested case-control analysis, use of 
biologic medications (OR 1.28, 95% CI 1.08-1.52), corticosteroids (OR 3.62, 95% CI 3.30-3.98) 
and proton pump inhibitor (PPI) (OR 1.14, 95% CI 1.03-1.25) in the preceding 120 days were 
significantly associated with pneumonia.
Conclusions—Patients with IBD are at increased risk for pneumonia. Use of corticosteroids 
particularly increases pneumonia risk.
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Patients with inflammatory bowel disease (IBD), particularly those treated with 
immunosuppression, are at increased risk for infectious complications. In fact, infectious 
complications are among the most common causes of death in patients with IBD.1 In the 
United States (US), community acquired pneumonia (CAP) is the leading infectious cause of 
death.2 The most common etiologic agent of CAP in the US is pneumococcal pneumonia. In 
2004, there were an estimated 866,000 cases of pneumococcal pneumonia in the US with 
estimated costs of 2.5 billion dollars.3
Little is known about the risk of pneumonia in IBD patients. In a recent study of death 
certificates, respiratory illness was identified as a common causes of mortality in IBD 
patients1 and bacterial pneumonia has been one of the most frequently reported 
complications in IBD clinical studies.4 In the rheumatoid arthritis (RA) population, 
pneumonia has been shown to be a major cause of morbidity and mortality.5, 6 In these 
patients, prednisone use has been associated with an increased risk of pneumonia 
hospitalization.5 The anti-tumor necrosis factor-alpha (anti-TNF) agents have been 
associated with an increased overall risk of infection in some,7, 8 but not all9 studies. Anti-
TNF agents have not been found to increase the risk of hospitalization for pneumonia in 
RA.5
To further evaluate these associations in the IBD population, we aimed to determine the risk 
of pneumonia in patients with IBD as compared to a non-IBD cohort. We also aimed to 
determine whether specific immunosuppressive medications increase the risk of pneumonia 
in patients with IBD.
Methods
We analyzed the procedural and outpatient pharmaceutical insurance claims contained in the 
LifeLink™ Health Plan Claims Database (IMS Health Inc, Norwalk, CT) for the period 
January 1, 1997 through December 31, 2009. This longitudinal, patient-level database has 
been used in previous epidemiologic studies of IBD.10, 11 The source database contains 
enrollment information on over 60 million persons from over 98 health plans across the U.S. 
The included health care plans capture a geographically diverse sample from across the 
United States. Only health plans that submit data for all members are included in the 
database, ensuring complete data capture and representative samples. Prior studies have 
reported the IMS Health database to be representative of the national commercially insured 
population on a variety of demographic measures, including geographic region, age, gender, 
and health plan type.12
Study Design
We performed a retrospective cohort study to determine the overall risk of pneumonia in 
IBD patients compared with a non-IBD cohort and a nested case-control study to determine 
the independent effects of medication use (immunosuppressive, anti-TNF therapy and 
corticosteroids) on pneumonia risk among patients with IBD. A similar design has 
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previously been used by our group10 and also by Gupta et al13 to evaluate the incidence of 
disorders in patients with IBD and the effects of various medications.
Cohort Study
Patient selection—All patients aged <64 years with at least 12 months of continuous 
health plan enrollment were eligible for inclusion in this analysis. We chose 64 as the upper 
age limit to avoid the possibility of missing data resulting from Medicare dual eligibility 
(which begins at age 65). Individuals were also required to have ongoing pharmacy 
coverage with their health plan in order to fully capture medication exposures. We identified 
cases of Crohn's disease (CD) and ulcerative colitis (UC) using a previously reported 
administrative definition expanded to include updated medications recently approved for 
IBD indications.14 The precise definition included patients with at least 3 health care 
contacts, on different days, associated with an International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9) diagnosis code for CD (555.xx) or UC (556.xx), or 
patients with at least 1 claim for CD or UC and at least 1 pharmacy claim for any of the 
following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-
mercaptopurine, azathioprine, methotrexate, infliximab, adalimumab, certolizumab pegol, 
natalizumab and enteral budesonide. For patients who had claims for both CD and UC, 
disease assignment was made according to the majority of the last 9 claims or the majority 
of total claims if there were fewer than 9. We matched each IBD patient to 4 non-IBD 
subjects by age, gender, calendar time and U.S. census region. Region of the country was 
defined by standard regional definitions from the United States Census Bureau. We ensured 
that each non-IBD subject was enrolled during the same calendar time as the IBD subject in 
order to account for the seasonality of pneumonia outcomes. All individuals with any ICD-9 
code for human immunodeficiency virus (HIV) (042-044.9) were excluded related to 
differences in susceptibility to infections.
Cohort lead time and follow-up—Each cohort member was required to have a 
minimum of 6 months of health plan enrollment prior to cohort entry. This “screening 
period” was used to assess potential confounders of interest. Additionally, anyone with a 
pneumonia claim in the last month of this “screening period” was excluded, as this was 
considered to represent a prevalent pneumonia. Each member of cohort was followed until 
the first diagnosis of pneumonia, or, if none, until censoring at the earlier of one of two 
events: discontinuation of primary or pharmacy insurance coverage, or age > 64.
Assessment of outcome (pneumonia)—Pneumonia was defined as 1) any 1 ICD-9 
code for bacterial pneumonia (481, 482.xx-483.xx, 485, 486) combined with a prescription 
for a systemic antibiotic or 2) any hospital confinement code accompanied by one of the 
above ICD-9 codes for bacterial pneumonia. For the first definition, the antibiotic 
prescription had to be filled in the time period of 1 week prior to 1 week after the pneumonia 
ICD-9 code. Antibiotic prescriptions for any of the following classes (any day supply) were 
included in the definition: macrolide class (erythromycin, clarithromycin, azithromycin), 
penicillin class (amoxicillin, ampicillin, oxacillin, penicillin, dicloxacillin, nafcillin, 
oxacillin, amoxicillin/clavulanate), 3rd or 4th generation fluroquinolone class (levofloxacin, 
moxifloxacin, gatifloxacin, gemifloxacin), 3rd or 4th generation cephalosporin class 
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(cefdinir, cefixime, cefotaxime, cefpodoxime, ceftibuten, ceftizoxime, ceftriaxone, 
cefoperazone, ceftazidime, cefepime) or tetracycline class (tetracycline, minocycline, 
doxycycline). Of note, ciprofloxacin (a second generation fluoroquinolone) was not included 
as part of the pneumonia outcome, as this antibiotic is not a “respiratory fluoroquinolone”15 
and is often used for an indication of IBD independent of infection. A similar definition for 
outpatient pneumonia consisting of medication dispensing and ICD-9 codes has been used in 
prior studies of community acquired pneumonia using administrative data.16 A more 
sensitive secondary definition of pneumonia consisting only of any one of the above ICD-9 
codes for bacterial pneumonia was then investigated.
Assessment of exposures—All exposure assessment occurred during the 6 month 
“screening period” prior to cohort entry. Health care utilization was estimated in a 
continuous fashion by the total of days with at least one health care contact over the time 
period. Utilization has been measured in this fashion in prior pharmacoepidemiology 
studies.17 Comorbidities were assessed using the Quan update18 of the validated Deyo 
comorbidity index for administrative data.19 Medication use, including immunosuppressive 
and biologic medications, was assessed in the exposure period in an any/none fashion. 
Additionally, as proton pump inhibitor (PPI) use can be associated with IBD and also with 
pneumonia, any PPI use was also extracted during the exposure period.
Evaluation of an Alternate Cohort—In order to cross-validate the outcome of 
pneumonia within our dataset, we also investigated the risk of pneumonia in a separate 
cohort of individuals with diabetes mellitus as compared to a non-diabetic cohort, using the 
same methodology as that used in the IBD cohort. Diabetes was chosen as a reference 
population due to the known increased risk of pneumonia20 and death from pneumonia in 
this population.21 Diabetes was defined using any 2 separate ICD-9 codes for diabetes 
(250-250.7).
Statistical analysis: We used descriptive statistics to summarize characteristics of patients 
with and without IBD. Continuous variables are reported as mean +/− standard deviation or 
median and interquartile range (IQR), and categorical variables are reported as percentages. 
We then calculated incidence rates of pneumonia (per 100,000 person-years) and used 
incidence rate ratios (IRRs) and 95% confidence intervals (CIs) to compare the incidence of 
pneumonia in IBD and non-IBD patients. We also performed subsequent analyses, 
stratifying by region of the country (defined by United States census groups),age (in 
decades), and disease type (UC vs CD). To control for confounding, we assessed for 
possible violation of the proportional hazards assumption via log-log plots. As the 
assumption was not violated, we used Cox proportional hazards models to calculate hazard 
ratios (HRs) and 95% CIs for the risk of pneumonia in the IBD cohort as compared to the 
non-IBD cohort, controlling for health care utilization and comorbidities. Analyses were 
repeated stratified by CD versus UC and within the alternate diabetes cohort.
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We next conducted a case-control study evaluating the association between corticosteroids, 
immunosuppressive or biologic anti-TNF medication use and pneumonia. This study was 
nested within the previously defined cohort of patients with IBD.
Selection of cases and controls—Cases were those IBD patients who were diagnosed 
with pneumonia, and controls were those IBD patients without pneumonia. Each case 
patient was matched on gender, age, geographic region, disease type (CD or UC), and 
duration of follow-up to 4 IBD patients who did not have pneumonia using incidence 
density sampling. In this sampling technique, a case patient can also be a control patient, 
provided that the case patient has not yet been diagnosed with pneumonia (has not yet 
become a case) at the time he or she is selected as a control. Once a case is diagnosed with 
pneumonia, he or she is no longer eligible to become a control, or a case again. A total of 
756 patients were included as both cases and controls. Each control was assigned an index 
date identical to the matched case's date of pneumonia, in order to account for seasonality.
Assessment of outcome (pneumonia)—The outcome was outpatient or inpatient 
pneumonia, as defined within the cohort study by ICD-9 codes, antibiotic prescriptions and 
hospital confinement codes.
Assessment of exposures
Medication Use: The primary medications evaluated included azathioprine and 6-
mercaptopurine (thiopurine class), methotrexate, tacrolimus and cyclosporine (calcineurin 
class), mycophenolate mofetil, infliximab, adalimumab, and certolizumab pegol (biologic 
anti-TNF class) and systemic corticosteroids. PPI use was also assessed, as this could be 
associated with both exposure and outcome. Medication exposures were analyzed with 
respect to the amount of time preceding the diagnosis of pneumonia in cases or the 
corresponding index date in controls. All exposures were defined as at least 1 outpatient 
pharmacy claim occurring during the 120 days prior to pneumonia diagnosis.
Potential confounders: Data on utilization and comorbidities were also included as 
exposure variables in the case-control study. These variables were assessed during the 6 
month exposure period prior to pneumonia diagnosis. Utilization was defined in a 
continuous fashion as total number of days with at least one health care contact. 
Comorbidities were assessed through the Quan update18 of the validated Deyo comorbidity 
index19 for administrative claims data.
Statistical analysis: Characteristics of cases and controls were described using descriptive 
statistics. We then used conditional logistic regression to calculate odds ratios (ORs) and 
95% CIs for each medication exposure related to the outcome of pneumonia. We 
constructed a full model by using all potential confounders and eliminated these 
confounders via a backwards elimination strategy by using a change in estimate approach 
(threshold of <10% change). Analyses were performed for patients with IBD and also 
stratified by UC and CD diagnosis.
Long et al. Page 5














The cohort study population included 108,604 patients with IBD. Of these, 50,932 had CD, 
56403 had UC and 1,269 had IBD with unknown type. There were a total of 434,416 
individuals in the non-IBD comparison cohort. The median length of follow up within this 
cohort was 24 months (IQR 12-42) with a range from 1-138 months after the 6 month 
“screening” period. Length of follow-up was similar for CD (34 months, IQR 19-51) and 
UC populations (36 months, IQR 21-54), while significantly less in the non-IBD comparison 
cohort (21 months, IQR 10-38). Characteristics of the patients with IBD as compared to the 
non-IBD cohort are shown in table 1. There was increased health care utilization, 
immunosuppressive medication use and PPI use among the IBD cohort as compared to the 
matched non-IBD cohort, as expected. These same factors were increased in those with CD 
as compared to those with UC. Among the IBD cohort, there were also slightly higher rates 
of liver disease and COPD as compared to the non-IBD cohort.
For patients with IBD, the overall annual incidence of pneumonia was 138/10,000, 
compared to 76/10,000 in the non-IBD cohort (IRR 1.82 95% CI 1.75-1.88) (figure 1). The 
risk was somewhat greater for CD as compared to non-IBD (IRR 2.05 95% CI 1.94-2.15) 
than for UC as compared to non-IBD (IRR 1.62 95% CI 1.54-1.71). The incidence of 
pneumonia was then evaluated in strata of age, with the highest incidence in the 60+ age 
strata (226/10,000). On adjusted Cox analysis, controlling for comorbidities, health care 
utilization, and PPI use, the relative risk remained elevated in the overall IBD population 
(HR 1.54, 95% CI 1.49-1.60). Compared to non-IBD controls, the risk was greater for CD 
(HR 1.71, 95% CI 1.62-1.80) than for UC (HR 1.41, 95% CI 1.34-1.48). Analyses were also 
performed using the alternate definition of pneumonia (any 1 ICD-9 code). The effect size 
estimate remained similar with this alternate definition, with an IRR of 1.83, 95% CI 
1.78-1.89 for pneumonia risk in the IBD cohort as compared to the non-IBD cohort.
In the alternate diabetes cohort, the risk of pneumonia in diabetics as compared to non-
diabetics was elevated to a similar extent (IRR 2.26, 95% CI 2.17-2.35). The overall 
incidence of pneumonia among diabetics was 178/10,000 as compared to 79/10,000 in the 
non-diabetic cohort. In adjusted analyses, adjusting for health care utilization and 
comorbidities, the risk estimate remained similar (HR 1.84, 95% CI 1.76-1.93).
In the nested case control study, 4856 IBD patients with pneumonia were matched to 18928 
IBD patients without pneumonia. The characteristics of the populations are shown in table 2. 
Patients with pneumonia had significantly more comorbidities, particularly COPD. Those 
with pneumonia also had significantly higher health care utilization and immunosuppressive 
medication use. PPI use was also associated with pneumonia. In the adjusted analyses, 
corticosteroid use (OR 3.62, 95% CI 3.30-3.98), biologic use (OR 1.28, 95% CI 1.08-1.52) 
and PPI use (OR 1.14, 95% CI 1.03-1.25) were independently associated with pneumonia in 
the overall IBD population. Interestingly, calcineurin inhibitor use was associated with 
lower risk. Similar risk estimates were seen when stratified by CD or UC. Crude and 
adjusted analyses are shown in table 3 for specific medication use in the overall population, 
and by IBD subtype.
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In this large cohort of commercially insured Americans, we have demonstrated an increased 
risk of pneumonia in patients with IBD as compared to the general population, with an 
adjusted effect estimate of HR 1.54, 95% CI 1.49-1.60. Additionally, we found a particularly 
increased risk of pneumonia among patients on corticosteroids (OR OR 3.62, 95% CI 
3.30-3.98), a mild to moderate increased risk in patients on anti-TNF agents (OR 1.28, 95% 
CI 1.08-1.52), and no increased risk associated with other classes of IBD medications.
Streptococcus pneumoniae is the most common cause of community acquired pneumonia 
(CAP), accounting for about 36% of cases of CAP in the general population. Vaccination 
against invasive pneumococcal disease is currently available in the US for both children and 
adults. Pneumococcal vaccine is recommended in IBD immunization guidelines.22 
Therefore, studying pneumonia is important in IBD, as 1) pneumonia is associated with 
substantial costs, morbidity and mortality and 2) complications from pneumonia may be 
preventable through vaccination.
In this large cohort of commercially insured Americans, we have demonstrated an increased 
risk of pneumonia in patients with IBD as compared to the general population, with an 
adjusted effect estimate of HR 1.54, 95% CI 1.49-1.60. Additionally, we found a particularly 
increased risk of pneumonia among patients on corticosteroids, a mild to moderate increased 
risk in patients on anti-TNF agents (OR 1.28, 95% CI 1.08-1.52), and no increased risk 
associated with other classes of IBD medications. These findings are particularly 
noteworthy, considering that pneumonia is 1) associated with substantial costs, morbidity 
and mortality, and 2) often preventable, given that vaccination against Streptococcus 
pneumonia, the most common cause of community acquired pneumonia (CAP) accounting 
for about 36% of cases of CAP, is currently available for both children and adults.
To our knowledge, this is the first epidemiological study of the incidence and medication-
specific risk factors for pneumonia in patients with IBD. However, these findings are of 
similar direction and magnitude to prior studies in the RA population. Wolfe et al 
demonstrated an increased risk for pneumonia hospitalization (HR 1.7, 95% CI 1.5-2.0) for 
patients with RA on corticosteroids, including a dose related increase in risk.5 Coyne et al 
found the overall annual incidence of lower respiratory tract infection (LRTI) in patients 
with RA was 2.3% with a mortality rate of 22.5%. Corticosteroids were also associated with 
an increased risk of hospital admission with LRTI in this study.6 The anti-TNF agents have 
been associated with increased risk of hospitalization for infection in patients with RA,8 
while other disease modifying agents (DMARDs) such as methotrexate were not. Other 
studies have not found an increased risk of serious hospitalized infection associated with the 
anti-TNF class, although there may be a relative increased risk with infliximab in the RA 
population.9
We also investigated the age-specific risks of pneumonia in patients with IBD, and found the 
highest relative risks in the younger (≤ 30 years) group, with the highest absolute risk in the 
elderly (61-64). This is not dissimilar to the general population and the previously described 
studies of RA,5, 6 where elderly individuals are at the highest risk for pneumonia. In the IBD 
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population, the greatest absolute differences in mortality rates for IBD as compared to the 
general population also occur in the elderly.23 As in the general population, we also found 
that comorbidities, including COPD, were additional risk factors for pneumonia in the IBD 
population.
Our study has also confirmed two known associations, which help to substantiate the 
validity of our novel IBD-related findings. First, the relative risk of pneumonia in IBD, 
particularly for those with CD (HR 1.71, 95% CI 1.62-1.80), was on par with the relative 
risk in a separate diabetes population (HR 1.84, 95% CI 1.76-1.93). Other studies have 
found diabetes to be associated with an increased risk of pneumonia (HR 1.92, 95% CI 
1.84-1.99)20 and death from pneumonia (HR 1.67, 95% CI 1.45-1.92).21 Additionally, 
recent data show an increased risk of pneumonia associated with PPI use. The mechanism 
behind this increased risk is hypothesized to be overgrowth of bacteria due to acid 
suppression in the stomach, which may increase the risk of micro-aspiration of bacteria, and 
therefore pneumonia.24 We found an increased risk of pneumonia associated with PPI use in 
our IBD population (unadjusted OR 2.21, 95% CI 2.04-2.39, adjusted OR 1.14, 95% CI 
1.03-1.25). Such findings are consistent with a recently published meta-analysis of 
pneumonia risk with PPI use (OR 1.36, 95% CI 1.12-1.65).24
There are notable strengths to this study of pneumonia in IBD. We were able to include a 
large sample size. We also had great geographic diversity, with patients from all regions of 
the US. By drawing from a large number of health plans of varying size, type, and location, 
we believe these results to be broadly generalizable to the commercially insured US 
population. We obtained complete data on all billed outpatient prescriptions in order to 
completely capture medication exposures; rather than relying on patient recall. We were also 
able to account for health care utilization, as we had access to all health care contacts within 
the database. By studying an alternate cohort of patients with diabetes, who are known to 
have an increased risk of pneumonia, we were able to substantiate our outcome in a separate 
reference population. We were also able to account for other pharmacologic exposures, such 
as PPIs, that have been associated with pneumonia and may be more common among 
individuals with IBD. Finally, we were able to account for comorbidities through a validated 
comorbidity index for administrative data.18, 19 This is particularly important, as 
comorbidities are known to be associated with pneumonia risk.
There are also several limitations to this study of administrative claims data. There is the 
possibility of misclassification of exposure and outcome related to the lack of clinical detail. 
We did use an IBD exposure definition previously used by our group10, 11 that requires 
multiple health contacts and/or IBD related prescriptions. A similar, but even less specific, 
administrative case definition has been validated by Herrinton et al. The Herrinton definition 
was found to have a sensitivity exceeding 90% and a PPV exceeding 80% for overall IBD.25 
We used an outcome definition of pneumonia that required both ICD-9 code and antibiotic 
dispensing. A similar definition of ICD-9 codes with antibiotic dispensing has been used in 
prior studies of pneumonia,16 although this definition has not been validated. We required 
both components (ICD-9 and medication dispensing), as prior validation studies of ICD-9 
codes alone have been found to be imprecise.26 Any measurement bias in this definition 
would be non-differential by IBD or non-IBD status and would therefore bias our estimate 
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towards the null value. We also performed a sensitivity analysis around the outcome 
definition by investigating a more sensitive definition consisting of any 1 ICD-9 code. The 
effect estimate for pneumonia risk with this definition did not change. Further support for 
the validity of the administrative definition used in this study is that the incidence of 
pneumonia in both the IBD and comparison cohorts was highest in the oldest age strata. 
Another limitation to this study is that the elderly (>age 65) and uninsured were not 
represented in our population. The lack of older persons in our study population does not 
affect the validity of the relative risks (IRRs, HRs, ORs) we presented in the context of the 
under 65 population. Finally, we were unable to account for certain exposures that may be 
related to the outcome, particularly smoking status. We were able to control for chronic 
obstructive pulmonary disease (COPD), which has been used as a proxy for smoking status 
in other studies using administrative data.
In conclusion, we believe that the increased risk of pneumonia in patients with IBD, 
particularly those treated with corticosteroids, should be viewed as a call to action. 
Pneumococcal vaccination is safe, effective, widely available, and known to prevent 
complications of pneumococcal pneumonia. Unfortunately, current vaccination efforts in the 
IBD population are lagging. In one tertiary care setting, only 9% of patients with IBD 
reported pneumococcal vaccination.27 As response to vaccination can be impaired with 
immunosuppression,28 the optimal time to vaccinate individuals with IBD is likely at 
diagnosis. Knowing risk factors for pneumonia in the IBD population, such as age and 
comorbidities, may increase awareness and promote prevention and/or early treatment. 
Additionally, awareness of the medication-specific risk factors: corticosteroids, anti-TNF 
agents and PPIs, may provide for timely intervention and ultimately improve outcomes.
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Table 2
Characteristics of the IBD Population by Pneumonia (matched characteristics include age, IBD type, gender, 
region)
Characteristics No Pneumonia (n=18928) Pneumonia (n=4856)
n % or median (IQR) n % or median (IQR) p value
*
Age
** 18928 47 (35-55) 4856 47 (35-55) 0.32
Gender (% male) 8087 42.7 2083 42.9 0.83
IBD type
    Crohn's disease 9572 50.6 2453 50.5 0.04
    Ulcerative colitis 9276 49.0 2369 48.8
    Unknown 80 0.4 341 0.7
Utilization
^ 18928 5 (1-11) 4856 13 (7-24) <0.01
Region
    East 3530 18.7 904 18.6 0.99
    Midwest 8649 45.7 2229 45.9
    South 2858 15.1 731 15.1
    West 3891 20.6 992 20.4
Comorbidities
    Cardiac 317 1.7 352 7.3 <0.01
    Diabetes mellitus 1219 6.4 596 12.3 <0.01
    Liver disease 498 2.6 329 6.8 <0.01
    Renal 226 1.2 205 4.2 <0.01
    COPD 1423 7.5 1935 31.6 <0.01
    Rheumatologic 401 2.1 288 5.9 <0.01
# Comorbidities= 18928 0 (0-0) 4856 1 (0-1) <0.01
Medications
%
    Biologic+ 587 3.2 292 6.0 <0.01
    Thiopurine& 1617 8.5 593 12.2 <0.01
    Calcineurin$ 52 0.3 43 0.9 <0.01
    Corticosteroid 1485 7.9 1531 31.5 <0.01
    5-ASA 4417 23.3 1314 27.1 <0.01
    PPI 2471 13.1 1182 24.3 <0.01
Source: IMS Health, LifeLink™ Health Plan Claims Database, From 1997 to 2009
*
p value by Pearson's chi square for categorical variables, Wilcoxon rank sum for continuous variables
**
Age at time of pneumonia (case) or index date (control)
^
Defined as total number of days (continuous) with any health care contact over observation period
=
Number of comorbities from Charlson comorbidity index
%
Any use over observation period
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